Core Viewpoint - Mindray Medical is pursuing an H-share listing in Hong Kong to enhance its global strategy and capitalize on international market opportunities, aligning with China's "14th Five-Year Plan" for high-level openness and innovation in medical devices [1][2][3] Group 1: Listing Strategy - The primary goal of the Hong Kong listing is to establish an international capital platform to support the company's globalization strategy, rather than merely raising funds [2] - Mindray aims for international market revenue to account for 70% of total income, with domestic revenue at 30%, indicating a shift towards a more balanced international revenue structure [2][3] - The company has a strong financial position, with cash reserves of 17.13 billion yuan as of September 2025, and has maintained a high dividend payout ratio since its A-share listing in 2018 [1] Group 2: Global Market Position - Mindray Medical is currently among the top 30 global medical device companies and aims to break into the top 20, with a long-term goal of reaching the top 10, necessitating annual revenues of at least 10 billion USD [3][4] - The global medical device market is approximately 4 to 5 times the size of the Chinese market, presenting significant growth opportunities [3][4] Group 3: Innovation and R&D - The company emphasizes innovation as its core driver, with over 5,000 R&D engineers and annual R&D spending exceeding 10% of revenue [5][6] - Mindray has developed a digital healthcare ecosystem integrating equipment, IT, and AI, aimed at extending quality medical resources to underserved areas [5][6] - The company is committed to addressing key healthcare challenges in China, such as accessibility and affordability, through technological advancements [6] Group 4: Future Outlook - Mindray plans to leverage its Hong Kong listing as a new starting point to deepen its domestic market presence while accelerating its global expansion [6] - The company aims to achieve a 70% international revenue share and establish itself as a leading player in the high-end manufacturing sector globally [6]

Core Viewpoint - The company, Mindray Medical, has submitted its application for a Hong Kong IPO, aiming to enhance its global presence and innovation capabilities through the raised funds [1][4]. Group 1: IPO and Fund Utilization - The IPO will combine public offerings in Hong Kong with international placements, with the specific scale to be determined based on market conditions [1]. - The funds raised will primarily be used for increasing global R&D investment, exploring potential global mergers and acquisitions, and enhancing the global sales network and supply chain capabilities [1][4]. Group 2: Business Development and Market Position - Mindray Medical is a leading global medical device company, covering multiple product lines and holding a significant market share in various segments [2]. - The company is projected to achieve a revenue of 36.7 billion yuan in 2024, with a compound annual growth rate (CAGR) of over 18% from 2017 to 2024 [2]. Group 3: R&D and M&A Strategy - As of June 30, 2025, the company plans to invest approximately 12.8 billion yuan in R&D, with over 5,200 specialized R&D personnel and a significant number of patents filed [3]. - Mindray has actively pursued acquisitions since its A-share listing, including notable purchases of companies in Finland, Germany, and China to enhance its product offerings and supply chain [3]. Group 4: Globalization and Market Opportunities - The global medical device market is expected to grow from $456.6 billion in 2020 to $623 billion in 2024, with a CAGR of 8.1% [5]. - Mindray has established a comprehensive global network, with localized production in 11 countries and a significant international workforce, enhancing its operational resilience and market responsiveness [6]. Group 5: Competitive Position and Future Outlook - Mindray's international revenue reached 16.4 billion yuan in 2024, with over 50% of its revenue coming from international markets as of Q3 2025 [6]. - The company has improved its global ranking in the medical device industry, moving from 36th in 2020 to 23rd in 2023, indicating a positive trajectory in market competitiveness [7].

Core Viewpoint - Mindray Medical (300760), a leading domestic medical device company, has submitted its application for a Hong Kong IPO, aiming for a dual listing in both A-share and H-share markets, with joint sponsors being Huatai International and JPMorgan [1] Group 1: IPO and Fundraising - The IPO will combine public offerings in Hong Kong with international placements, with the specific issuance scale to be determined based on market conditions [1] - The funds raised will primarily be used to enhance global R&D investment, innovate products and digital solutions, explore potential global mergers and collaborations, and improve global sales networks and supply chain capabilities [1] Group 2: Business Performance and Market Position - Mindray Medical is the only Chinese company among the top 30 global medical device firms, with a comprehensive product line that includes monitoring devices, anesthesia systems, ventilators, defibrillators, blood cell analyzers, and ultrasound equipment, all ranking in the top three globally [1] - The company is projected to achieve a revenue of 36.7 billion yuan in 2024, with a compound annual growth rate (CAGR) of over 18% from 2017 to 2024, and a net profit CAGR exceeding 24% [2] Group 3: Competitive Advantages - In the in-vitro diagnostics sector, Mindray is the largest provider in China and the second largest globally for blood cell diagnostics, as well as the largest domestic provider of chemical luminescence immunoassays [3] - The company holds significant market shares in various categories, including being the largest provider of monitoring devices in China and the second largest globally [3] Group 4: R&D and Innovation - Mindray has invested approximately 12.8 billion yuan in R&D, employing 5,200 specialized R&D personnel across 12 global centers, and has filed over 12,240 patents [4] - The company emphasizes its commitment to independent innovation, continuously increasing R&D investment to meet international standards [4] Group 5: Strategic Directions - Mindray is transitioning towards a sustainable growth model centered on recurring revenue from consumables and digital services, while maintaining its leadership in equipment sales [5] - The company plans to enhance its presence in minimally invasive surgery and intervention fields, aiming to shift from one-time equipment sales to a sustainable, repeat-purchase revenue model [5] Group 6: Future Growth and Market Expansion - By the first half of 2025, recurring revenue from consumables is expected to account for about 40% of total revenue, with significant growth potential in the domestic market [6] - The IPO is seen as a strategic move to bolster investments in digitalization, recurring revenue, and internationalization, which are critical for future growth [6]

Group 1 - Mindray Medical has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and JPMorgan serving as joint sponsors [1] - Mindray's six major product lines, including monitors, anesthesia systems, ventilators, defibrillators, blood cell analyzers, and ultrasound imaging equipment, rank among the top three in the global market [1] - The listing aims to build an international capital platform, with funds raised to enhance R&D and overseas expansion, potentially accelerating penetration into emerging markets and breakthroughs in high-end markets [1] Group 2 - Insilico Medicine has announced a strategic drug development collaboration with Eli Lilly, leveraging Insilico's AI drug discovery platform and Eli Lilly's expertise in drug development and disease research [2] - This collaboration signifies an upgrade in the partnership, building on a previous software licensing agreement established in 2023 [2] Group 3 - YuanDa Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its innovative drug, Laitling, which treats allergic rhinitis in adults and children [3] - Laitling was approved by the U.S. FDA in January 2022 and has also been approved in multiple countries, including Australia, Russia, South Korea, the UK, and the EU [3] - As a compound formulation, Laitling offers patients a more convenient and effective treatment option, improving patient compliance [3]

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容 概不負責，對其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. 深圳邁瑞生物醫療電子股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或承銷團成員表示同意： 本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》送呈香港公司註冊處處長登記前，本 公司不會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務 請僅依據於香港公司註冊處處長註冊的本公司招股章程作出投資決 ...

Core Insights - The article highlights the approval of eight innovative medical devices by NMPA, indicating a growing trend in the medical technology sector in China [1] Group 1: Company Profiles - Shanghai Xinhong Life Science Co., Ltd. focuses on innovative ultrasound cardiovascular medical technology, leveraging a team with extensive experience in R&D and commercialization [2] - Beijing Bairen Medical Technology Co., Ltd. specializes in high-value medical devices derived from animal sources, with a strong portfolio of 17 approved Class III medical devices [3] - Suzhou Meichuang Medical Technology Co., Ltd. is dedicated to developing innovative medical devices for peripheral vascular and tumor intervention, utilizing proprietary ePTFE materials [4] - Suzhou InnoCore Medical Technology Co., Ltd. is focused on absorbable magnesium alloy materials and advanced orthopedic devices, holding multiple core technologies [4] - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is the largest medical device manufacturer in China, reporting a revenue of 16.743 billion yuan in the first half of 2025, a decrease of 18.45% year-on-year [6] - Beijing Aikang Yicheng Medical Equipment Co., Ltd. is a pioneer in the commercialization of additive manufacturing technology for orthopedic implants, with several products having received NMPA registration [7] - Chunfeng Huayu (Suzhou) Intelligent Medical Technology Co., Ltd. focuses on innovative spinal surgery robotics, enhancing surgical efficiency through automation [8] - Jingyu Medical Technology (Suzhou) Co., Ltd. specializes in deep brain stimulation systems, with products approved for various neurological conditions [9] Group 2: Market Trends - The approval of innovative medical devices reflects the increasing emphasis on advanced medical technologies in China, addressing clinical pain points and enhancing patient care [1][2][3][4] - The performance of established companies like Mindray indicates a challenging market environment, with significant revenue declines amidst ongoing industry adjustments [6] - The emergence of startups in the medical technology space, such as Chunfeng Huayu and Jingyu Medical, showcases the potential for innovation and growth in specialized medical fields [8][9]

Core Viewpoint - Suzhou Mediston Medical Technology Co., Ltd. (referred to as "Mediston") reported a significant turnaround in its financial performance for the first half of 2025, achieving a net profit of 28.33 million yuan, compared to a loss in the same period last year [1] Financial Performance - The company achieved operating revenue of 135 million yuan and a total profit of 31.14 million yuan during the reporting period [1] - The net profit attributable to shareholders was 28.33 million yuan, marking a return to profitability compared to the previous year [1] Technological Advancements - Mediston completed the domestic software localization and innovation transformation, ensuring compatibility with major domestic hardware and software platforms, meeting national technology requirements [1] - The products are now compatible with Huawei's Kunpeng series servers and support various domestic operating systems, including Tongxin UOS and Kylin [1] - The company has optimized its database compatibility with major domestic databases, ensuring efficient and stable operation in a secure environment [1] AI and Product Development - The company upgraded its anesthesia, critical care, and emergency systems with AI integration and deep fusion with the DeepSeek model [1] - The intelligent doctor assistant module provides clinical decision support, helping doctors formulate precise treatment plans based on patient history and examination data [1] Strategic Collaborations - Mediston's health and wellness robot project has initiated strategic collaborations with multiple medical institutions, focusing on the application of embodied intelligent robots in the health and elderly care sectors [2]